CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Name
nihms907485.pdf
Description
Accepted version
Size
736.19 KB
Format
Adobe PDF
Checksum (MD5)
1aab2cd730d48f8fa1f0ab0868f13777
Author(s)
Alsaiari, Shahad K
Eshaghi, Behnaz
Du, Bujie
Kanelli, Maria
Li, Gary
Wu, Xunhui
Zhang, Linzixuan
Chaddah, Mehr
Lau, Alicia
Yang, Xin
Date Issued
October 16, 2024
Journal
Nature Reviews Materials
Publisher
Springer Science and Business Media LLC
Citation
Alsaiari, S.K., Eshaghi, B., Du, B. et al. CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells. Nat Rev Mater 10, 44–61 (2025).
Version
Author's final manuscript
Abstract
CRISPR–Cas9 genome editing technology is a promising tool for genetically engineering immune cells and modulating immune systems. Although ex vivo genome editing of immune cells has reached clinical trials, in vivo application is still restricted by the instability and inefficient delivery of CRISPR–Cas9 components to immune cells through circulation. In this Review, we summarize ex vivo and in vivo strategies to deliver CRISPR–Cas9 components to both non-immune and immune cells. We review the progress made in non-immune cells because it offers insights that can be applied to advancing research in immune cells. We also discuss principles and challenges of immune system modulation using CRISPR–Cas9 genome editing technology.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution-Noncommercial-ShareAlike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41578-024-00725-7
